Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, reports the study, „Analysis of Cost-Effectiveness in Switzerland for a New Implantable Device to Treat Chronic Gastroesophageal Reflux Disease,“ was published recently by the Journal of Medical Economics.
The comprehensive health economic analysis published in this study found that RefluxStop™ is highly likely to be a cost-effective treatment for GERD in Switzerland against Nissen fundoplication, Magnetic Sphincter Augmentation (LINX System) and PPI-based medical management. Higher improvement of patient’s quality of life (Quality Adjusted Year Life (QALY)) scores and lower costs were achieved by RefluxStop™ compared to Nissen fundoplication and the LINX system. The data was published in The Journal of Medical Economics, which serves an international audience and publishes rigorously peer-reviewed economic assessments of novel therapeutic and device interventions.
The study authors represent a partnership between the York Health Economics Consortium, UK and leading reflux centers of excellence in Switzerland, including Dr. med. Yves Borbély, Department of Visceral Surgery and Medicine, Inselspital Bern University Hospital, Switzerland, and Prof. Dr. med. Joerg Zehetner, Department of Visceral Surgery, Swiss1Chirurgie, Hirslanden Klinik Beau-Site Switzerland.
